Barclays PLC Has $651,000 Stock Position in AngioDynamics, Inc. (NASDAQ:ANGO)

Barclays PLC boosted its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 81.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 83,582 shares of the medical instruments supplier’s stock after purchasing an additional 37,394 shares during the quarter. Barclays PLC owned 0.21% of AngioDynamics worth $651,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the stock. Quarry LP boosted its stake in AngioDynamics by 75.1% during the second quarter. Quarry LP now owns 6,047 shares of the medical instruments supplier’s stock worth $37,000 after buying an additional 2,594 shares in the last quarter. CWM LLC boosted its position in shares of AngioDynamics by 981.3% during the 3rd quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier’s stock valued at $76,000 after acquiring an additional 8,832 shares in the last quarter. Mackenzie Financial Corp bought a new stake in AngioDynamics in the second quarter valued at about $80,000. Wealth Enhancement Advisory Services LLC acquired a new position in AngioDynamics in the third quarter worth about $86,000. Finally, AE Wealth Management LLC acquired a new position in AngioDynamics in the second quarter worth about $87,000. 89.43% of the stock is owned by institutional investors.

Analyst Ratings Changes

ANGO has been the topic of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price target on shares of AngioDynamics in a research note on Tuesday, December 10th. Canaccord Genuity Group reduced their target price on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, October 4th.

AngioDynamics Trading Up 1.2 %

ANGO opened at $9.16 on Thursday. The stock has a market capitalization of $372.21 million, a P/E ratio of -1.50 and a beta of 0.68. AngioDynamics, Inc. has a 12 month low of $5.26 and a 12 month high of $9.58. The firm’s fifty day simple moving average is $7.69 and its 200 day simple moving average is $7.19.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Thursday, October 3rd. The medical instruments supplier reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.04. The firm had revenue of $67.50 million for the quarter, compared to analysts’ expectations of $67.93 million. AngioDynamics had a negative net margin of 83.95% and a negative return on equity of 5.86%. The company’s revenue for the quarter was down 14.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.12) EPS. On average, equities research analysts predict that AngioDynamics, Inc. will post -0.41 EPS for the current fiscal year.

Insider Buying and Selling

In other AngioDynamics news, CEO James C. Clemmer purchased 20,000 shares of the stock in a transaction that occurred on Monday, October 7th. The shares were acquired at an average cost of $6.03 per share, with a total value of $120,600.00. Following the completion of the transaction, the chief executive officer now owns 681,582 shares in the company, valued at $4,109,939.46. The trade was a 3.02 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders have acquired 22,568 shares of company stock valued at $135,847. 5.40% of the stock is owned by insiders.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.